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Immunotherapy Drugs
Ruixue Wang and Shuhong Luo
Abstract
Orf is one of the most widespread viral diseases worldwide, usually benign and 
self-limiting, and mainly affects not only sheep and goats, but also various other 
ruminants and mammals. The causative agent, orf virus (ORFV) is a member of 
the genus parapoxvirus, owing to its zoonotic importance and ability to cross-
infect other species sporadically. ORFV encodes virulence and immunomodulatory 
factors that interfere with host inflammatory effect and antiviral immune mecha-
nisms and induces a transient and complex cytokine response, initially represented 
by Th1-related cytokines followed by Th2-related cytokines. The ORFV has 
evolved several mechanisms to survive in the presence of the immune system, 
resulting in repeated infections. Currently, ORFV has been developed as vaccines 
in veterinary field. The unique host immune escape ability obtained by ORFV has 
made it one of the important candidates for prevention and treatment of various 
diseases (including chronic viral diseases, tumor, and liver fibrosis).
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1. Introduction
Orf was first discovered in Europe in 1920. At present, the main geographi-
cal distribution of the pathogen is not clear, which is considered to be prevalent 
worldwide since orf exists in all areas where sheep exists. The United States of 
America, Germany, Korea, Japan, India, Argentina, Malaysia, Egypt, and China 
have reported the occurrence and prevalence of the disease, which has brought 
a certain degree of loss to the sheep industry. The causative agent, orf virus 
(ORFV), also known as contagious pustular stomatitis (contagious ecthyma) 
virus, belongs to the parapoxvirus genus of poxvirus family and causes nonsys-
temic cutaneous disease by mainly infecting sheep and goats. In recent years, the 
cases of human, camel, yak, red squirrel, cat, domestic reindeer, etc. infected 
by ORFV have been reported. This indicates that the host range of the virus is 
expanding.
After being infected by ORFV, the infected animals begin with the appear-
ance of erythema on the lips, tongue, nose, and breast of sheep, then develop into 
papules, blisters, and pustules, and finally form crusts, characterized by prolifera-
tive inflammation (Figure 1). The course of the disease is mostly an acute infection, 
healed within 1-2 months, but there are also cases of chronic persistent infection 
records. The disease rarely causes animal death unless host immunosuppression 
or secondary infection occurs, but there are also reports of a high mortality rate of 
93% in young goats.
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2. ORFV genome biology
ORFV belongs to the subfamily parapoxvirus of the poxvirus family. Other mem-
bers of this genus include pseudovaccinia virus (PCPV), bovine papular stomatitis virus 
(BPSV), and parapoxvirus of red deer in New Zealand (PVNZ). The mature ORFV 
particles are 250–280 mm in length and 170–200 nm in width, and elliptical and coiled 
shaped, while the immature virus particles are conical, brick-shaped, and special coiled 
spherical particles (Figure 2). The surface of the virus particles showed a characteristic 
braided helical structure of cross-arranged around the long axis of the virus particles 
for eight-shaped winding. There are other ways of winding, and the virus particles 
encapsulated outside the capsule. ORFV replicates and matures in the cytoplasm, 
encoding polymerases associated with virus replication and transcription.
ORFV is a linear double-stranded (ds) DNA virus with a genome size of 134–
139 kb. The average G + C content of the virus genome was approximately 64%. The 
content of G + C in the ORFs in the central coding region of the genome is not very 
different, but the ORFs in the two ends of the genome are very different, which are 
even less than 50% in some regions, such as ORFV127. Mercer believes that the ter-
minal is based on the conservation of the genome sequence (OVSA00, OVIA82, and 
NZ2) and the transcriptional initiation of the gene in three strains of the virus. Even 
though the G + C content of seven ORFVs in ORFV102–104, 109–112 is quite different 
from the genome average G + C content, and the homology of the encoded proteins 
is low, but the G + C content between different strains is very close [2]. The content 
of G + C in BPSV genome terminal variant region is similar, too, which is a marker of 
poxvirus members. Like other members of the poxvirus family, it has a large central 
coding region in the middle of the genome and an inverted terminal repeat (ITR) at 
both ends, which had covalently closed terminal hairpin structures (Figure 3).
Figure 1. 
Typical clinical signs of ORFV infection in sheep (cited from reference [1]). Proliferative skin lesions of two 
infected sheep around the mouth, nostrils (arrows), and the eyelids (arrowheads).
3Orf Virus: A New Class of Immunotherapy Drugs
DOI: http://dx.doi.org/10.5772/intechopen.81535
There are many studies on the whole gene sequencing and analysis. The first 
genome of two strains (SA00 and IA82) was sequenced in 2003 by the Mei Dao 
Animal Disease Center of the US Department of Agriculture. OVSA00 was identi-
fied as the reference sequence of the virus. Mercer submitted the full genome 
sequence of the NZ2 strain in 2006, and McGuire sequenced strain (D1701) and 
submitted it to GenBank. Luo submitted the full genome sequence of the ORFV 
Figure 2. 
The electron microscopy of the ORFV (cited from reference [1]). The predominantly immature virions (arrows 
and arrowheads) (A) and intracellular mature virions (B) under transmission electron microscopy. (C) The 
extracellular virions under atomic force microscopy. Scale bars = 500 nm.
Figure 3. 
The structure of the genome of ORFV strain NA1/11. The genome of ORFV is 138 kb, encoding 132 genes, and 
includes highly variable terminal regions, responsible for virus virulence and pathogenesis, and relatively 
conserved central regions with a high GC content for viral replication and virus morphogenesis. There are 16 
novel genes unique to parapoxvirus, with putative virulence-host range functions.
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strains of China. Up to now, NCBI has included 10 complete genome sequences of 
ORFV (Table 1).
Delhon et al. conservatively estimated about 130 coding genes in the ORFV 
genome [5]. Through analysis of the genome sequence of NZ2 strain, 132 possible 
coding genes were found in the genome of this virus strain. Transcription initiation 
elements (TAAAT) existed before the coding regions of the two genes and were found 
in BPSV. Similar conserved sequences also exist, but these two genes only exist in 
parapoxvirus but not in orthopoxvirus. Mercer et al. checked the ORFs of 24 genes 
of ORFV, which showed high interspecific variability mainly in the two terminal 
variant regions [7]. Many genes located in the core region have been identified. 
The ORFV050 gene, similar to L4R of vaccinia virus (VACV), encodes the DNA-
binding virion core protein VP8 [8]. ORFV057 encodes protein OH1, analogous to 
the VACV structural protein VH1, that can dephosphorylate phosphatidylinositol 
3, 5- bisphosphate, and plays a role in virion maturation [9]. The ORFV011 (B2L) 
gene, a homolog of the F13 L gene of VACV, encodes a major envelope protein of 
42 kDa, which is thought to be a lipase. Additionally, the viral A32L gene (ORFV108) 
encodes an ATPase involved in virion DNA packaging [10]. Virulence genes, coding 
genes related to host pathogenesis and immunoregulatory genes are located in the ITR 
regions of the ORFV genome, such as ORFVs 007, 020, 112, 117, 119, 125, and 132.
3. The immunomodulatory ability of ORFV
3.1 ORFV and immunomodulatory ability
ORFV is widely recognized as having a powerful host immunoregulatory function. 
ORFV can quickly mediate humoral and adaptive immune responses. After being 
infected with ORFV, many cells of the innate immune system are activated and induce 
the secretion of chemokines and cytokines. Neutrophils, natural killer (NK) cells, and 
dendritic cells (DC) are recruited at the site of infection. In the early stage of infection, 
ORFV mainly induces the Th1-type immune response. Peripheral immune cells secrete 
IFN-γ, TNF-a, IL-6, IL-8, IL-12, IL-18, and then Th2-type immune response appears, 
mainly inducing secreting of IL-4, IL-10, IL-1 receptor antagonists (IL-1RA). The 
conditioning of complement and antigen-presenting-cell (APC)-mediated antigen 
presentation are important steps to activate the immune response.
Strain Species 
of origin
Country 
of origin
No. of 
predicted 
genes
Genome 
size 
(bp)
ITR 
size 
(bp)
G + C 
content
Geninfo 
identifier
Reference
D1701 Sheep Germany 288 134,038 325073632 [3]
YX Goat China 132 138,231 3446 63.8 913203877 [4]
NP Goat China 124 132,111 2426 63.8 913204143 [4]
GO Goat China 132 139,886 3964 63.6 913204010 [4]
SJ1 Goat China 129 139,112 4153 63.6 913204268 [4]
HN3/12 Sheep China 132 136,643 2794 63.7 1240685690 [2]
SA00 Goat USA 132 139,962 3936 63.4 40019123 [5]
NA1/11 Sheep China 134 137,080 3020 63.6 632123481 [6]
IA82 Sheep USA 132 137,241 3092 64.3 40019122 [5]
NZ2 Sheep New 
Zealand
132 137,820 3389 64.3 74230714 [7]
Table 1. 
Summary of complete genomic sequence data of 10 ORFV strains.
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ORFV and some of its encoded proteins have a good immunomodulatory 
function. Homologous alignment analysis of the host sequence and the viral gene 
sequence has identified that some ORFV genes have corresponding immunoregula-
tory functions, including coding for IL-10 homologous proteins, chemokine bind-
ing proteins, secretory inhibitors of GM-CSF and IL-2, vascular endothelial factor 
(VEGF), and interferon resistance protein. The main targets of IFN resistance genes 
are host cytokines, chemokines, NF-κB signaling pathway, and apoptosis pathway. 
The synergistic effect of these proteins has strong immunomodulatory effects on 
ORFV.
ORFV is the only virus that contains the gene encoding lL-10 found in the poxvi-
rus family. vIL-10, a 21.7 kDa protein with remarkable homology to IL-10, which is 
encoded by ORFV127 gene, plays an important role in immunosuppression through 
inhibition of cytokine syntheses, such as TNF-α and IL-8, IFN-γ [11], suppression 
of the maturation and functionality of DC [12, 13], blockage of Th1 cell activation 
indirectly through weakening the antigen processing, and presentation ability 
of APC. The direct role of the vIL-10 gene in virulence was demonstrated using 
an ORFV lacking the IL-10 gene, which showed attenuated properties in animal 
experiments [14], while vIL-10 can exert immunostimulatory effects by inducing 
moderate compensatory immune activation [15].
One of the characteristics of ORFV infection is the proliferation of capillar-
ies and the increasing of permeability in the dermis, which is caused by viral 
VEGF. The deletion of VEGF gene leads to vascular permeability reduction, inhibi-
tion of epidermal cells and inactivation of VEGF receptors (VEGF-2) [16, 17]. Viral 
VEGF, sharing 16–27% of amino acid identity with its homolog VEGFs (VEGF-A, 
VEGF-B, VEGF-C, VEGF-D), has the same function as VEGFs: promoting the pro-
liferation of epidermal cells, inducing the proliferation of host vascular endothelial 
cells and increasing the permeability of capillary vessel wall. Interestingly, VEGF 
variants are observed in different strains of ORFV. Despite such variation existing, 
the functional domains of the protein exhibit conserved structure. Studies reported 
that a recombinant virus strains lacking VEGF gene reduced vascular changes char-
acteristic of natural infections, with less proliferation of blood vessels and dermal 
edema, pustule, and scab formation in ORFV pathogenesis [18].
In the early stage of ORFV infection, the orf virus interferon resistance pro-
tein (OVIFNR) encoded by ORFV20 binds to the viral replication intermediates 
and prevents the termination of IFN-induced virus-carrying protein translation. 
OVIFNR shares 31% sequence similarity with the E3L protein of VACV, and the 
C-terminal region with the binding activity of dsRNA (or viral replication interme-
diates) was the necessary region to prevent the antiviral activity of IFN and associ-
ated with pathogenicity and host tropism. OVIFNR eliminates the antiviral effect 
of IFN through the synthesis of the dsRNA-dependent protein, like protein kinase 
(PKR) [19]. The dsRNA-activated PKR is one of the main antiviral proteins induced 
by IFN. Activated PKR phosphorylates the translation initiation factor eIF2-α and 
impairs protein synthesis to inhibit viral replication [20]. OVIFNR not only com-
pete with PKR to bind to viral replication intermediates but also inhibit the activity 
of PKR, thus preventing host cell interference from terminating the translation of 
viral proteins.
The ORFV007-encoded dUTPase clusters with mammalian counterparts and 
is more similar to mammalian dUTPases than to dUTPases from other poxviruses 
[21]. The virulence of ORFV with the 007-gene deletion is significantly lower than 
that of natural ORFV.
Chemokine-binding protein (CBP), the coding product of ORFV112, has 
similarities in structure and function with CBP II of orthopoxvirus and rabbit 
poxvirus. It can bind and inhibit chemokine and prevent chemokine-receptor 
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interaction. When chemokines bind to their receptor, the G protein-coupled recep-
tor, the white blood cells were recruited and activated in viral infection. In addi-
tion, chemokines interact with glycosaminoglycan (GAG) and establish a gradient 
liquid phase that guides leukocytes through the endothelium into tissues. ORFV-
CBP and CBP-II have high affinity to some CC chemokines, such as monocyte 
chemoattractant protein 1 (MCP1), macrophage inflammatory protein 1 (MIP1), 
and regulated on activation, normal T cell expressed and secreted (RANTES), 
which can produce chemotactic effects of both nucleus/macrophage and T lym-
phocyte toward inflammation. Although ORFV encodes a number of secreted 
anti-inflammatory factors, the deletion of the CBP gene severely attenuated viral 
virulence and pathogenesis [22].
GIF is encoded by ORFV117, expressed in the late stage of infection, and has 
the dual activity of inhibiting host GM-CSF and IL-2, thus inhibiting host immune 
activity [23]. The gene is conserved in different ORFV strains and also exists in 
other parapoxvirus strains, but the amino acid sequence similarity between ORFV 
and BPSN is only 40%. However, the function of GIF in virulence and pathogenesis 
is not yet known.
3.2 ORFV and immune evasion
After infection, sheep produces antibodies to four or five immunodominant 
antigens [24–26]. Murine monoclonal antibodies recognizing 42 kDa envelope pro-
teins, the 10 kDa putative fusion protein, and 65 kDa antigens have been described 
that can discriminate between the different parapoxvirus species [27, 28]. In spite 
of an apparently normal immune response to infection, sheep can be repeatedly 
infected, suggesting that, in common with other large DNA viruses, ORFV has 
evolved an immune evasion strategy [29, 30].
ORFV infection stimulated hyperplasia of epidermal cells and capillaries growth 
with increased vascular permeability, which allows increased virus replication and 
formation of scabs on wound healing. Scabs are rich in virus particles and provide 
temporary refuge for viruses to escape from immunization. The antiviral effect 
of IFN is the first line of defense against viral infection; ORFV evades immune 
clearance by inhibiting IFN-stimulated genes expression mediated by the JAK/STAT 
signaling pathway [31]. In addition, ORFV also can induce apoptosis mediated by 
CD95 pathway [15] or inhibit the pro-inflammatory NF-κB signaling, a crucial 
regulator of host innate immune responses. For pathogens, interfering with the 
activation of NF-κB is a particular strategy against host defense mechanisms. The 
regulation of NF-κB includes the regulation of IκB in the cytoplasm, and post-
translational phosphorylation, acetylation, and methylation in the nucleus. The 
ORFV 002, 024, 073, 119, and 121 genes have been reported that play roles in NF-κB 
pathway regulation [32–38].
ORFV002 is an early and late stage virus gene, mainly located in the nucleus. 
ORFV002-encoded protein can inhibit the activation of NF-κB pathway induced by 
TNF-α and ORFV virus infection, which may through interfering the interaction 
between NF-κB-p65 and P300 in the nucleus block the acetylation of NF-κB-p65 
Lys310 when phosphorylation occurs at ORFV002 Ser 276 [32, 33]. The 52 amino 
acids of ORFV002 N terminal may interact with protein S100A4 [34].
The ORFV024-encoded protein combines with LAGE3 to inhibit the phosphory-
lation of IKKs complex and then affects the phosphorylation of NF-κB-p65, inhibits 
the host immune cells to secrete some important cytokines, and regulates the host’s 
immune response [35].
ORFV119 blocks the NF-κB signaling largely in a pRb-dependent manner, by 
inhibiting IKK complex activation early in infection [36]. ORFV119 interacted 
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with TNF receptor-associated factor 2 (TRAF2), an adaptor protein recruited to 
signaling complexes upstream of IKK in infected cells, in a LxCxE motif-dependent 
manner, which leads to inhibition of NF-κB signaling.
The ORFV073 protein, 188 amino acids with a molecular weight of 21.8 kDa, 
whose protein at 149, 160, and 166 locations contained three predicted and partially 
overlapping nuclear localization signals, is located in nucleus during viral replica-
tion and be related to gene expression regulation. When the ORFV073 gene was 
deleted in the ORFV genome, the expression of chemokines and other pro-inflam-
matory genes was significantly increased, and most of the gene expression changes 
were regulated by the NF-κB transcription factor family [37].
After infected with an ORFV121 gene deletion mutant, NF-κB-mediated gene 
transcription was increased, while the expression of ORFV121 in cell cultures signifi-
cantly decreased NF-κB-regulated reporter gene expression, suggesting that NF-κB 
inhibitor binds to and inhibits the phosphorylation and nuclear translocation of 
NF-κB-p65 in the cell cytoplasm, thus providing a mechanism for the inhibition of 
NF-κB-p65 phosphorylation and nuclear translocation [38].
4. Diagnosis and treatment
At present, there is no international standard for the diagnosis of amniotic aph-
thous ulcer, mainly based on the typical clinical symptoms and laboratory tests to 
diagnose. As shown in Figure 4, current laboratory diagnoses include PCR, ELISA, 
electron microscopy, histopathology, Western blotting.
The orf is mainly observed by the morphology of virus particles. A human case 
of orf was identified by transmission electron microscopy in a 20-year-old woman 
with two painful pruritic lesions on her left index finger [39]. Under the transmis-
sion electron microscopy, multiple typical ORFV particles existed with brick-
shaped morphology, consisting of a central DNA-containing core surrounded by a 
bilayered capsid.
Figure 4. 
The diagnosis methods and treatment of orf.
Systems Biology
8
Histopathological features of the orf lesion include vacuole and swelling of 
keratinocytes, interstitial degeneration, marked epidermal hyperplasia, micro-
swelling in the epidermis, aggregation of neutrophils, DC, T cells and B cells in 
the subcutaneous tissue, and formation of the crust. Eosinophilic inclusion bodies 
were also evident in the infected cytoplasm, but not at all stages of infection. There 
are mononuclear cells infiltrating into the dermis, such as phagocytes, lympho-
cytes, and eosinophils. In secondary infection, a dermal infiltration of neutrophils 
appeared [40].
A variety of primary cells and cell lines can be used to isolate ORFV. Primary 
lamb testicular cells and primary lamb kidney-trophoblast cells, which were 
originally used by Plowright et al., are the most common in the prozonal cells 
[41]. The primary fetal lamb muscle cells [42] and turbinate cells [5], fetal 
bovine lung cells [43], Madin-Darby bovine kidney cells [44], and vero cells 
[45] were also used. ORFV can induce cytopathy in these cells after inoculation 
of the first generation or blindly transmitted for one to two generations. The 
common cytopathic effects are aggregation, fusion, shrinkage, and cell detach-
ment. Eosinophils in the cytoplasm can be observed by staining of infected cell 
lines. Parapoxvirus culturing, in general, is considered to be difficult, with a 
need for many passages before observing cytopathic effects, such as ballooning, 
wounding, degeneration of cells, etc.
Serum neutralization tests, commonly used for the detection of antibodies, 
are not considered to be the method of choice for primary diagnosis, as immunity 
to ORFV is mainly cell-mediated, and neutralizing antibodies are usually at small 
concentrations. Suspected serum with a titer of 8 and 20 or above is considered as 
positive for orf infection, in serum neutralization test and complement-fixation 
test, respectively [46].
Indirect ELISA with a purified virus as coating antigen, peroxidase complex pro-
tein A, G and chimeric A/G as secondary antibodies can be used to detect antibody 
levels in different animals [47]. The method has been successfully applied to detect 
the virus in camels [48], lambs [49], and humans [50] suspected to be infected with 
the disease.
A 40 kDa immunogenic protein has been found in the positive sera of infected 
animals by Western blotting. Similarly, two proteins of approximately 22 and 
20 kDa have been found by this method.
Different PCR methods can be used for rapid diagnosis of ORFV. A conven-
tional PCR assay based on amplification of the ORFV B2L gene, a homolog of 
the F13 L gene of VACV, encodes a major envelope protein of 42 kDa, which is 
supposed to be a lipase, and was used to detect parapoxvirus species. A duplex 
PCR assay using A29 gene (413 bp) and H3L gene (708 bp) has the potential to 
differentiate capripoxviruses from ORFV [51]. A single-step PCR method was 
applied for the rapid differential diagnosis of ORFV infections [52]. Primers 
targeting the A32L gene, besides, the complete sequences of another two viral 
genes were also investigated: the B2L, and E3L genes, which encodes a dsRNA-
binding protein. A conventional PCR assay combined with DNA sequencing can 
be used to distinguish among the different parapoxvirus species [53]. A sensitive 
and specific SYBR Green I real-time PCR assay was performed to quantitatively 
detect ORFV [54].
Restriction fragment length polymorphism (RFLP) of the genome is a powerful 
tool for analyzing the molecular characteristics of poxvirus, which can potentially 
distinguish different strains of amniotic stomatitis virus. Restriction enzyme 
fragments are obtained by enzyme (EcoRI, BamHI, and HindIII) digestion. 
Commercialized kits with random amplified polymorphic DNA have been used to 
distinguish virus strains from large numbers of species. Loop-mediated isothermal 
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amplification targeting B2L, DNA polymerase, and F1L genes have been developed 
and proven to be effective diagnostic tools [55, 56].
The ORFV has a strong ability to adapt to the external environment and has 
a strong resistance, even after a year in the sheep pen around, the virus still has a 
strong infectivity. But the virus is sensitive to temperature changes, suitable for 
the humid environment, and can be killed at 60°C in 30 min. Besides, the use of 
antiviral drugs has been applied in human and animal orf infections with satisfying 
results, such as Cidofovir [57, 58].
The virus is virulent for about a year when it is added to 50% glycerol saline 
and stored at 4°C. In the actual feeding process, generally choosing to use 20% hot 
grass and wood ash solution, 10% lime milk, 2% sodium hydroxide solution, and 
1% acetic acid for disinfection can kill the virus, while using 2% sodium hydroxide 
solution to kill the virus in 5 min. The treatment for human orf is often focused 
on secondary infection. Previous reports have described speeding up the heal-
ing process with topical imiquimod [59] and the antiviral cidofovir cream [60]. 
Cryotherapy has also been used successfully to treat orf cases, especially in immu-
nocompromised patients [61].
5. Clinical applications
ORFV is widely recognized as a virus with powerful host immunoregulatory 
function, but neutralizing antibody in ORFV infection is rare [27], and passive 
transfer of antibody-rich colostrum or serum does not protect lambs from infection 
[62, 63].
In veterinary medicine, ORFV is widely used as a new type of preventive and 
immunomodulatory preparation. Activated or inactivated ORFV preparations 
have a dose-dependent immunomodulatory function. Therefore, based on ORFV, 
drugs for a variety of infectious animal diseases have been developed (Baypamun; 
Zylexis). For example, Baypamun was used to suppress stress-related infections 
in horses, and clinical data showed a significant 40% reduction in the incidence of 
stress-related infections in the medication group [64]. Its therapeutic effect has also 
been verified in other animals, such as the treatment of bovine herpesvirus type 
1, chronic stomatitis or infectious peritonitis in cats, and breast tumors in dogs. 
Inactivated ORFV can induce spontaneous regulation of cytokine responses in 
mice, such as up-regulation of Th1 cytokines (IL-12, IL-18, and IFN-γ), activation 
of CD14 and TLR-mediated monocyte activation, and release of anti-inflammatory 
Th2-related cytokines.
5.1 Antiviral preparations
Activated or inactivated ORFV makes many kinds of animals to fight dif-
ferent viral diseases. The ORFV has significant antifibrous activity in CCL4-
mediated liver fibrosis [65]. The inactivated ORFV agents with a low dose (only 
500,000 virus particles) are more effective in transgenic mice than the standard 
3TC for HBV infection [66]; thus, it can be used as the candidate antiviral 
agent for the treatment of human HBV. Inactivated ORFV has anti-HCV activ-
ity in vitro and transgenic mice model [67]. In addition, ORFV can prevent the 
recurrence of fatal herpes simplex virus (HSV) and recurrence of genital herpes 
in Guinea [68].
ORFV can be used as a carrier to produce new animal recombinant vaccines. 
Recombinant ORFV vector induces an antiviral response in various animals. 
Recombinant pseudorabies virus glycoprotein gC or gD can be used to prevent 
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infection in mice and pigs [69, 70]. ORFV recombinant with protein P40 can 
induce the immune protection of rats from infection, and effectively eliminated 
the Borna disease virus in the brain [71]. ORFV recombinant classical swine fever 
virus protein E2 can also make pigs immune to classical swine fever virus (CSFV) 
[72]. Recombinant ORFV expressing hemagglutinin (HA) or nucleoprotein (NP) of 
highly pathogenic avian influenza virus H5N1 protects mice against H5N1 and H1N1 
influenza viruses [73]. A recombinant virus strain D1701-VP1 of rabbit blast virus 
VP60 gene expression induced the infected cells releasing goblet-like particles to 
protect the rabbit from ORFV attack [74].
5.2 Oncolytic virus
Live or inactivated ORFV induces antitumor immune responses in multiple 
tumor models. Fiebig et al. reported for the first time that inactivated ORFV 
has antitumor effects in a variety of tumor metastasis models, such as mouse-
transplanted malignant melanoma B16F10 and human breast cancer MDA-MB-231 
models [75], and found that NK cells play an important role in the antitumor of 
ORFV. After neutralizing IFN-γ, the antitumor effect disappeared, while the anti-
NK-1.1 antibody partially weakened the antitumor activity of ORFV by inhibiting 
the activity of NK and NKT cells. Inactivated ORFV inhibited tumor growth in 
a mouse MDA-MB-231 tumor model without NK and lacking functional T and B 
lymphocytes. Whether inactivated or active ORFV is used to treat mouse tumor 
models, NK cells play an important role in antitumor. A study by Rintoul further 
confirmed that ORFV inhibits tumor growth of melanoma and colorectal cancer, 
and proved that ORFV could play an antitumor role by activating NK cells and 
stimulating their secretion of cytokines IFN-γ and granzyme B [76]. Tai et al. found 
that surgery mediated the dysfunction of NK cells [77]. Intraoperative injection of 
ORFV improves the function of NK cells, thereby reducing intraoperative metas-
tasis and prolong survival. Recently, a study of the virus strain CF189, which is the 
high similarity with the ORFV virus strain NZ2 obtained by homologous recombi-
nation, showed that CF189 effectively kills three negative breast cancer cells with 
time and dose dependence [78].
6. Conclusion
ORFV causes orf, a nonsystemic, highly contagious, ubiquitous disease of 
sheep and goats [79], which is characterized by maculopapular and proliferative 
lesions affecting the skin around the mouths, nostrils, and teats. Virus virulence 
and immunomodulation genes of ORFV contribute to combat local inflammatory 
response, innate immunity (including apoptosis, NK cell activation, and antiviral 
response), and immune adaptation. Therefore, ORFV has been used in veterinary 
medicine as preventive and therapeutic immunomodulatory agents. Moreover, live 
or inactivated ORFV preparations exhibit immunomodulatory effects, with thera-
peutic efficacy demonstrated for various diseases, including infectious diseases and 
tumors.
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